At the end of June, Vaxart said that the Covid-19 vaccine they were researching had been selected by the US government for Operation Warp Speed – a federal initiative to speed up the process of preparing anti-Covid-19 products.

The race to develop a Covid-19 vaccine is still ongoing.

This trend is helping senior leaders and shareholders of pharmaceutical and medical businesses benefit.

Moderna’s Covid-19 vaccine is being tested.

However, some companies are being noticed by the US government because they may be using the Operation Warp Speed program for advertising.

The vaccine was selected for an animal testing program that a federal agency coordinated with Operation Warp Speed.

Some US Department of Health officials have expressed concern about whether companies like Vaxart are exaggerating their role in Warp Speed to inflate stock prices.

However, in the New York Times, Vaxart CEO Andrei Floroiu affirmed that the company `still complies with governance rules and only makes decisions that benefit the company and shareholders.`

Trading stocks at favorable times is generally legal.

`This is not the right time for pharmaceutical industry leaders to make money from the crisis. Every day, many Americans have to sacrifice because of the pandemic. But pharmaceutical companies see this as a day to make money.`

Leaders of many companies have earned millions, even tens of millions of dollars thanks to Covid-19 vaccine and drug research activities.

Regeneron spokeswoman Alexandra Bowie said most stock sales are scheduled in advance and are performed automatically when the price hits a certain level.

In January, Moderna – a 10-year-old vaccine company in Cambridge, Massachusetts, announced that it was researching a Covid-19 vaccine.

While some transactions are planned in advance, others are opportunistic.

Leaders and shareholders of Luminex, Quidel and Emergent BioSolutions also sold shares worth $85 million after announcing they were researching vaccines, drugs or other testing methods.

In many businesses, directors and shareholders receive large stock options right before the company announces good news, causing the value of these options to increase sharply.

In April, when the stock price was below 24 USD, Novavax issued a series of bonus shares to all employees `to recognize the extraordinary efforts in vaccine preparation`.

However, to date, Novavax stock price has increased to more than 130 USD.

However, Vaxart is still the fastest place to make money.

After taking office in June, Floroiu received stock options worth $4.3 million.

`Vaxart is creating a breakthrough in the vaccine world,` Floroiu said in an online meeting last week. `It’s normal to make a profit from the Covid vaccine, as long as you don’t profit.`